Mydecine Innovations Group Stock Cash Per Share
| MYCOF Stock | USD 0.01 0.0003 5.00% |
Fundamental analysis of Mydecine Innovations allows traders to better anticipate movements in Mydecine Innovations' stock price by examining its financial health and performance throughout various phases of its business cycle.
Mydecine |
Mydecine Innovations Group Company Cash Per Share Analysis
Mydecine Innovations' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Mydecine Innovations Cash Per Share | 0.04 X |
Most of Mydecine Innovations' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mydecine Innovations Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Mydecine Innovations Group has a Cash Per Share of 0.04 times. This is 99.08% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash per share for all United States stocks is 99.2% higher than that of the company.
Mydecine Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mydecine Innovations' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mydecine Innovations could also be used in its relative valuation, which is a method of valuing Mydecine Innovations by comparing valuation metrics of similar companies.Mydecine Innovations is currently under evaluation in cash per share category among its peers.
Mydecine Fundamentals
| Return On Equity | -12.24 | |||
| Return On Asset | -1.76 | |||
| Current Valuation | 8.64 M | |||
| Shares Outstanding | 13.01 M | |||
| Shares Owned By Insiders | 8.71 % | |||
| Price To Book | 23.41 X | |||
| Price To Sales | 677.59 X | |||
| Revenue | 7.49 K | |||
| Gross Profit | 7.49 K | |||
| EBITDA | (23.14 M) | |||
| Net Income | (28.9 M) | |||
| Cash And Equivalents | 324.15 K | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 1.26 X | |||
| Book Value Per Share | (0.36) X | |||
| Cash Flow From Operations | (24.05 M) | |||
| Earnings Per Share | (4.68) X | |||
| Target Price | 140.0 | |||
| Number Of Employees | 11 | |||
| Beta | 3.42 | |||
| Market Capitalization | 5.94 M | |||
| Total Asset | 7.58 M | |||
| Z Score | -9.3 | |||
| Net Asset | 7.58 M |
About Mydecine Innovations Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mydecine Innovations Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mydecine Innovations using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mydecine Innovations Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in Mydecine Pink Sheet
Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.